Clik here to view.
Aroa Biosurgery Opens New Pathway for Advanced Wound Treatment Amidst...
SAN DIEGO Soft tissue repair company Aroa Biosurgery is stepping up to support clinicians and their patients who are battling to treat wounds amid disruption to many existing U.S. facilities for...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products...
View ArticleClik here to view.
武田薬品：エグゼクティブ報酬返還ポリシー（クローバックポリシー）の導入について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 (東証:4502) (NYSE:TAK)：...
View ArticleClik here to view.
Takeda Adopts Executive Compensation Recoupment Policy
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced that its Board of Directors approved an executive compensation recoupment policy (“clawback...
View ArticleClik here to view.
Notice Regarding Business Alliance Between Sanbio and Ocumension in the...
TOKYO SanBio Co., Ltd. (Keita Mori, Representative Director and President, hereinafter “SanBio”) (TOKYO:4592) hereby announces that SanBio has entered into a business alliance with Ocumension (Hong...
View ArticleClik here to view.
Modalis Obtains Access to Foundational CRISPR IP
TOKYO & CAMBRIDGE, Mass. Modalis Therapeutics Corporation (Modalis) today announced that the company has entered into a license agreement with Editas Medicine, Inc., under which Modalis has...
View ArticleClik here to view.
武田采用高管薪酬追回政策
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502/NYSE:TAK)（“武田”）今天宣布，其董事会批准了一项高管薪酬追回政策（“追回政策”）。该追回政策的采纳是武田为进一步加强其一流公司治理承诺所作不懈努力的一部分，并且与武田的同业一致。...
View ArticleClik here to view.
Promega GoTaq® Probe 1-Step RT-qPCR System Approved for Use in CDC’s COVID-19...
MADISON, Wis. Promega Corporation’s GoTaq® Probe 1-Step RT-qPCR System is now in a Centers for Disease Control and Prevention COVID-19 diagnostic protocol for emergency use. The Promega tool is an...
View ArticleClik here to view.
RECELL® System Data Accepted to 52nd Annual American Burn Association Meeting...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
SETi’s Violeds Technology Proves 99.9% Sterilization of Coronavirus...
COLUMBIA, S.C. Sensor Electronic Technology, Inc. (“SETi”), a leading global innovator of deep UV LED products and technology, announced that it has been successful in achieving 99.9% sterilization...
View ArticleClik here to view.
武田ADCETRIS® (brentuximab...
马萨诸塞州剑桥和日本大阪 (美国商业资讯)– 武田药品工业株式会社(TSE:4502/NYSE:TAK)（“武田”）今天宣布，欧洲药品管理局(EMA)人用药品委员会(CHMP)对ADCETRIS® (brentuximab...
View ArticleClik here to view.
Seoul Viosys and SETi’s Violeds Technology Proves 99.9% Sterilization of...
ANSAN, South Korea Seoul Viosys (KOSDAQ: 092190) and Sensor Electronic Technology, Inc. (“SETi”), leading global innovators of UV LED products and technology, announced that it has been successful...
View ArticleClik here to view.
フリアー、産業用モニタリングおよび高皮膚体温スクリーニングのためのスマート・サーマル・センサーを発売
米バージニア州アーリントン （ビジネスワイヤ） — フリアーシステムズ（NASDAQ：FLIR）は本日、FLIR...
View ArticleClik here to view.
FLIR推出用于工业监测和皮肤温度升高筛查的智能热传感器解决方案
弗吉尼亚州阿灵顿 (美国商业资讯)–FLIR Systems, Inc. (NASDAQ: FLIR)今日宣布推出FLIR A400/A700智能热传感器(Thermal Smart Sensor)和热图像流(Thermal Image...
View ArticleClik here to view.
武田薬品、未治療の全身性未分化大細胞リンパ腫成人患者を治療するためのアドセトリス（ブレンツキシマブ・ベドチン）とCHP（シクロホスファミド+ドキソルビシン...
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Celltrion’s COVID-19 Antiviral Treatment Enters the Next Phase of Development
INCHEON, South Korea Celltrion Group today announced its successful transition to the second phase of development for an antiviral treatment to fight the novel coronavirus (COVID-19) pandemic,...
View ArticleClik here to view.
EUSA Pharma和意大利Papa Giovanni XXIII医院提供Siltuximab治疗COVID-19患者的SISCO研究中期分析数据
英国赫默尔亨普斯特德和意大利贝加莫 (美国商业资讯)–专注于肿瘤学和罕见病的全球性生物制药公司EUSA Pharma今天发布Papa Giovanni XXIII医院申办的SISCO（Siltuximab In Serious COVID-19，Siltuximab治疗严重COVID-19）研究的初步结果1，该结果的依据是预先计划于2020年3月24日开展的数据分析。...
View ArticleClik here to view.
EUSA Pharmaとイタリアのパパ・ジョヴァンニ23世病院がSISCO研究でシルツキシマブ治療を受けたCOVID-19患者の中間解析データを発表
英ヘメルヘムステッド & 伊ベルガモ （ビジネスワイヤ） — オンコロジーと希少疾患に傾注する世界的バイオ製薬企業のEUSA Pharmaは本日、パパ・ジョヴァンニ23世病院が治験依頼主となるSISCO（Siltuximab In Serious...
View ArticleClik here to view.
知臨集団がCovar...
ニューヨーク （ビジネスワイヤ） — 感染症・希少疾患・代謝性疾患などの領域における未充足ニーズに対処するための新規治療薬の開発に傾注するバイオ製薬企業の知臨集団（Nasdaq:...
View ArticleClik here to view.
グローバルで血漿分画製剤領域をリードする企業による新型コロナウイルス感染症（COVID-19）に対する高度免疫グロブリン製剤の開発加速を目指した協力体制について
大阪 & 米国ペンシルベニア州キング・オブ・プルシア （ビジネスワイヤ） — CSL...
View Article